Τίτλος:
Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Purpose: Our aim was to examine the prognostic significance of ERbeta1 and ERbeta2 expression in ERalpha-negative breast carcinomas. Materials and methods: We evaluated nuclear and cytoplasmic expression of ERbeta1 and ERbeta2 by immunohistochemistry in a group of 95 patients with long follow-up. ERbeta1 and ERbeta2 status was correlated with clinicopathological parameters and disease outcome. Univariate and multivariate analyses of ERbeta1 and ERbeta2 as independent markers of disease-free survival (DFS) were carried out using the Cox proportional hazards model. Results: Nuclear ERbeta1 (nERbeta1) and nERbeta2 status was positively correlated (p = 0.01). nERbeta1 positivity was associated with low histological grade (p = 0.01) in all patients and in the nERbeta2-positive subgroup (p = 0.03) but not in the nERbeta2-negative (p = 0.27). nERbeta2 positivity was associated with lymph node involvement and tumor relapse in all cases (p < 0.00 and p < 0.00, respectively) and in the nERbeta1-negative subgroup (p < 0.00 and p < 0.00, respectively) but not in the nERbeta1-positive (p = 0.09 and p = 0.20, respectively). nERbeta2 positivity was associated with poor DFS in all patients (log-rank p <0.00), in the post-menopausal patient subgroup (log-rank p = 0.02) and in the HER2-negative (triple-negative) subgroup (log-rank p = 0.04). Cox multivariate analysis including ERbeta1, ERbeta2 and established clinicopathological variables highlighted ERbeta2 as an independent marker of early disease recurrence (hazard ratio 4.87; 95 % confidence interval 1.07-22.3; p = 0.04). Conclusion: High nERbeta2 is an independent marker of early relapse in ERalpha-negative breast carcinoma, and in particular, in the nERbeta1-negative, the post-menopausal patient and the triple-negative subgroups. These findings suggest that inhibition of expression and/or function of ERbeta2 could improve disease outcome. © 2013 Springer-Verlag Berlin Heidelberg.
Συγγραφείς:
Chantzi, N.I.
Tiniakos, D.G.
Palaiologou, M.
Goutas, N.
Filippidis, T.
Vassilaros, S.D.
Dhimolea, E.
Mitsiou, D.J.
Alexis, M.N.
Περιοδικό:
Journal of Cancer Research and Clinical Oncology
Λέξεις-κλειδιά:
estrogen receptor beta; estrogen receptor beta 1; estrogen receptor beta 2; unclassified drug, adult; aged; article; breast carcinoma; cancer prognosis; cancer recurrence; cell nucleus; clinical feature; correlation analysis; cytoplasm; disease course; disease free survival; estrogen receptor alpha negative breast carcinoma; female; follow up; histopathology; human; human cell; human tissue; immunohistochemistry; lymph node metastasis; major clinical study; multivariate analysis; postmenopause; priority journal; proportional hazards model; protein expression; protein function; triple negative breast cancer; univariate analysis, Adult; Aged; Breast Neoplasms; Cell Nucleus; Cytoplasm; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymph Nodes; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Survival Rate; Tumor Markers, Biological; Young Adult
DOI:
10.1007/s00432-013-1467-4
